异恶唑烷酮类耐药结核分枝杆菌的分离与鉴定。
Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis.
机构信息
TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA
出版信息
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01296-17. Print 2017 Oct.
Oxazolidinones are promising candidates for the treatment of infections. We isolated linezolid-resistant strains from H37Rv (Euro-American) and HN878 (East-Asian) strains; resistance frequencies were similar in the two strains. Mutations were identified in ribosomal protein L3 (RplC) and the 23S rRNA (). All mutant strains were cross resistant to sutezolid; a subset was cross resistant to chloramphenicol. Mutations in led to growth impairment and decreased fitness that may limit spread in clinical settings.
恶唑烷酮类是治疗感染的有前途的候选药物。我们从 H37Rv（欧美）和 HN878（东亚）株中分离出线唑烷酮耐药株；两种菌株的耐药频率相似。核糖体蛋白 L3（RplC）和 23S rRNA（）中鉴定出突变。所有突变株对苏替唑均交叉耐药；一部分对氯霉素交叉耐药。突变导致生长受损和适应性降低，这可能限制其在临床环境中的传播。
Zotero 插件